20 articles
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
18-month trial tested omega-3 supplementation in 774 older adults with low DHA/EPA levels and memory concerns to prevent cognitive decline.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Large 6-year study tested dietary interventions including caloric restriction and omega-3s in 330 people with mild cognitive impairment.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
32-person study explores how intermittent fasting affects blood vessel function and brain performance through protective pathways.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
A completed pharmacokinetic study tracks NAD precursors NR and NMN from bloodstream to brain, filling a critical gap in human data.
